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Advances in understanding aging processes and
their consequences are leading to the development
of therapies to slow or reverse adverse changes for-
merly considered to be “normal” aging and pro-
cesses that underlie multiple age-related conditions.
Estimating the effectiveness of candidate aging thera-
pies, whose effects on human aging may require
many years to determine, is a particular challenge.
Strategies for identifying candidate interventions can
be developed through multiple approaches, including
the screening of molecular targets and pathways
in vitro and in animal models, informed as well by
evidence from human genetic and epidemiologic
data. A number of recently established programs and
networks can serve as resources for such research.
For all these research approaches, from in vitro mo-
lecular studies to clinical trials, contributions of cell
and molecular biology are crucial and offer the pros-
pect of therapeutic advances that address fundamen-
tal biological processes as well as the clinically im-
portant challenges of aging.
Introduction
Considered most broadly, the concept of aging thera-
pies includes prevention and treatment of the variety of
conditions whose rate of occurrence increases with
age. Progress against many of these conditions has
been ongoing for several decades. Most of this has
stemmed from research on specific age-related condi-
tions rather than on aging per se, such as clinical trials
showing effective means of preventing cardiovascular
disease and diabetes in older persons. It is likely that
progress on these and other age-related conditions will
continue. This review deals principally with therapies
focused specifically on aging processes, specifically
those that contribute to disease or dysfunction. The
pronounced increase with age in incidence of most
conditions causing morbidity and mortality, as well as
long-term increases in the proportion of individuals sur-
viving to ages when the prevalence and severity of such
conditions are high, highlight the potential health bene-
fits of better interventions to modulate such aging pro-
cesses.
Aging therapies may be aimed at reversing age-
related changes once they have occurred or at deceler-
ating or preventing aging changes starting at various
points in the life span. A therapy that is effective for
one of these purposes may be ineffective or even*Correspondence: ehadley@nih.govcounterproductive for the other. An intervention started
before old age might slow a process that resulted in a
particular pathology in late life but have adverse effects
in individuals in whom that pathology is already pres-
ent. This, for example, has been suggested as a possi-
bility for effects of estrogens in regard to atherosclero-
sis and coronary heart disease.
Two therapeutic foci are of particular interest:
Changes with age previously considered to be “nor-
mal aging” but that have adverse consequences. Al-
though many age-related changes are asymptomatic
and are found in many or all persons, they are not nec-
essarily benign. As understanding of adverse effects of
a “normal” aging change progresses, the change may
be recognized as a disease or risk factor. A familiar ex-
ample is osteoporosis, which results in most cases
from progressive bone loss starting in middle age. Its
relation to fracture risk has been recognized for several
decades, and insights into its pathophysiology have led
to a variety of therapies. An analogous evolution has
occurred recently regarding age-related loss of muscle
mass: disability and other adverse conditions have
been linked to muscle loss of sufficient severity, for
which the term “sarcopenia” is now applied. Similarly,
as discussed below, there is increasing evidence that
an age-related increase in vascular stiffness may be a
risk factor for cardiovascular disease and that therapies
may be developed to enhance vascular compliance
and reduce cardiovascular mortality.
The importance of identifying adverse effects of age-
related changes and developing therapies that retard
or reverse such changes is highlighted by the fact that,
for many age-related conditions, currently known risk
factors only explain a modest proportion of the risk. For
example, chronologic age remains the strongest single
risk factor for cardiovascular disease, presumably re-
flecting effects of specific age-related changes whose
role has not yet been appreciated and which may be
modifiable once identified. Thus, new therapies to
counter aging changes whose role in disease risk is
identified could, when added to existing therapies, re-
duce risk for age-related conditions (or delay their on-
set) much more than is currently possible.
Fundamental mechanisms responsible for multiple
age-related pathologies. Several underlying processes,
many discussed elsewhere in this issue, that may regu-
late multiple aging changes have been proposed and
investigated. These include damage and repair of mac-
romolecules and other tissue components; regulation
of cell proliferation, differentiation, and death; control
of cellular bioenergetics; and control of genomic sta-
bility. The potential health benefits of an intervention
that modulates a mechanism that affects the develop-
ment of multiple adverse changes with age have fre-
quently been noted. In addition to the inherent effi-
ciency of a single intervention with multiple benefits,
this type of intervention could avoid problems of ad-
verse effects of a therapy for one age-related condition
on other age-related conditions (e.g., exacerbation of
Cell
558high blood pressure by nonsteroidal anti-inflammatory c
vdrug treatment for arthritis).
t
sIssues and Resources for Developing
oNew Human Aging Therapies
fIdentification and Evaluation of Potential Therapies
dParticularly for interventions whose effectiveness may
cdepend on starting early in life, a fundamental issue for
cthe development of aging therapies is the long time
mscale of human aging. Many proposed mechanisms of
gaging are postulated to act over the life span, so that
yeffects of interventions that decelerate aging changes
dmight be expected to diminish as the age when they
sare begun increases. This implies that testing of some
shuman interventions may need to begin at an early age
and continue for a long time. Even interventions started
lin late life to reverse age-related changes may take sev-
ieral years to show effects in humans. Thus, selection
Fof aging therapies for testing long-term effects in hu-
bmans is especially dependent on shorter-term evalua-
gtion of potential interventions. Such strategies include
Bthe following:
dIdentifying pathways regulating aging changes and
tpotential molecular targets for interventions. Choices
of potential therapeutic targets can be informed by
sevaluating genetic effects or interventions in short-lived
porganisms such as yeast, nematodes, fruit flies, and
Umice. During the past 10 years, many genetic changes
has well as interventions that increase longevity in these
tanimal models have been reported and may provide a
tbasis for developing promising human interventions.
nAlthough genetic manipulations may not be directly ap-
fplicable to humans, results of these experiments are
ahelpful in identifying pathways for possible pharmaco-
ilogical intervention.
o
Short-lived nematodes, fruit flies, and mice have
f
been particularly useful for identifying genes that influ-
t
ence longevity. Because this area has been extensively
g
discussed by Cynthia Kenyon in this issue of Cell (Ken- r
yon, 2005), we will only briefly mention the most salient g
results. A striking observation is that major effects on life p
span have been achieved by mutating genes that affect t
the signaling pathways related to insulin-like factors (Li- s
ang et al., 2003; Tatar et al., 2003). Significant effects have a
also been achieved from genetic manipulations that: (1) E
reduce ROS generation by mitochondrial electron trans- f
port (Feng et al., 2001; Knauf et al., 2002; Ishii et al., m
2004); (2) reduce food consumption (Miskin and Masos, c
1997; Lakowski and Hekimi, 1998); (3) increase expres- i
sion of antioxidant genes (Larsen, 1993; Mitsui et al., d
2002; Ruan et al., 2002), heat shock genes (Munoz, C
2003), or sirtuins (Tissenbaum and Guarente, 2001); or s
(4) modify the apoptotic (Migliaccio et al., 1999; Cohen n
et al., 2004) or proliferative (Vellai et al., 2003) potential n
of cells. A limited number of potential pharmacological i
interventions have also been identified including anti- w
oxidants (Melov et al., 2000) and compounds that mod- i
ulate protein deacetylase activity (Howitz et al., 2003;
Wood et al., 2004). e
Though human intervention studies based on factors m
identified in animal models are, for the most part, not o
likely to start until well into the future, in vitro studies o
dof human cells provide another means to identify espe-ially promising pathways and targets for human inter-
entions. This approach has not been used extensively
o date but has considerable potential. Though such
tudies do not directly test the effects of interventions
n human aging, they do allow testing effects of genetic
actors and interventions on specific functions (e.g., oxi-
ative stress resistance or insulin sensitivity) in human
ells, including tests in specific cell types, could provide
lues to their in vivo effects. These in vitro approaches
ay be amenable to creative and high-throughput strate-
ies. In addition, comparative studies on cells from
oung and old human donors may reveal age-related
ifferences in metabolic or signaling pathways that may
uggest targets for interventions to reverse or prevent
uch changes.
Recently, genetic epidemiologic studies of human
ongevity have begun to provide another means of
dentifying possible pathways and molecular targets.
or example, such studies have identified a relationship
etween exceptional longevity and variants of several
enes affecting lipoproteins (Schachter et al., 1994;
arzilai et al., 2003; Geesaman et al., 2003). The pro-
ucts of these genes may serve as targets for interven-
ions.
New technologies are facilitating high-throughput
trategies to identify potential therapeutic targets and
romising interventions in very short-lived species.
sing a dye-based assay for cell death, Gill et al. (2003)
ave developed a high-throughput assay for interven-
ions that delay death in nematodes. Using an RNA in-
erference screen of 5690 nematode genes, a large
umber of genes affecting mitochondrial function were
ound also to affect life span (Lee et al., 2003). Bauer et
l. (2004) have developed a rapid method to identify
nterventions that increase longevity of fruit flies, based
n the fact that mutations that change life span in fruit
lies also change the timing of gene expression pat-
erns. Because longer-lived flies express lethal reporter
enes later than control flies, flies with normal aging
ates can be killed off before flies with extended lon-
evity, so these long-lived flies can be enriched in the
opulation. This assay has also been successfully used
o test pharmacological interventions as well as re-
ponse to environmental conditions, showing, for ex-
mple, that resveratrol and lipoic acid but not vitamin
can increase fruit fly longevity. In addition, after identi-
ication of molecular targets modulating aging changes,
ultiple compounds that could affect these targets
an be screened. This approach has been applied to
dentify sirtuin activators that increase life span and
ecelerate aging in S. cerevesiae (Howitz et al., 2003),
. elegans, and D. melanogaster (Wood et al., 2004). It
hould be noted that NIH’s Roadmap Initiatives (http://
ihroadmap.nih.gov/) include efforts to establish tech-
ologies and infrastructure for high-throughput screen-
ng of molecules that impact specific metabolic path-
ays. These efforts will greatly facilitate aging research
n this area.
Laboratory mammalian studies testing intervention
ffects on outcomes. Interventions for testing in mam-
als can be selected based on findings from the types
f invertebrate studies described above, physiologic
bservations in mammals themselves, or epidemiologic
ata suggesting an effect of a particular factor in hu-
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ducted on the effects of interventions in abnormally
short-lived strains with specific conditions or genetic
defects as well as in long-lived wild-type strains. The
latter type of study is widely accepted as preferable for
studies to examine potential human applicability, and
the following discussion is confined to such studies.
The rapid discovery rate of findings from very short-
lived invertebrates, implicating potential therapeutic
targets for longer-lived species, offers challenges as
well as opportunities for mammalian studies: mamma-
lian studies of effects on life span and on other re-
sponses that require observation over an appreciable
percent of the life span require much more time than
analogous invertebrate studies. Hence, it is likely that
the fraction of candidate interventions suggested by in-
vertebrate studies that can actually be tested in mam-
mals will be quite limited. Expanding mammalian model
testing could help to reduce this discrepancy. Strate-
gies to help refine the selection of interventions sug-
gested by in vitro and invertebrate studies for mamma-
lian testing can also help. For example, it is likely that
many factors with positive effects on life span operate
on the same or convergent pathways (as has been
found for the multiple longevity-related genes that af-
fect the insulin-like peptide signaling pathways), and
sorting these factors into a limited number of pathways
will facilitate finding the most promising points on these
pathways for targeting preclinical and clinical interven-
tions. In addition, more information on functions of ho-
mologous proteins in invertebrate models and in mam-
malian models for therapeutic aging studies could help
to distinguish those targets for which mammalian inter-
ventions are likely to have positive effects from those
that affect pathways that are important in invertebrates
but not in mammals.
Few mammalian life span studies have tested inter-
ventions to modulate specific processes implicated in
the invertebrate studies discussed above. Antioxidant
studies have not shown substantial life span effects
(Golden et al., 2002), with the exception of moderate
extension in rodents by nitrone free radical spin-trap-
ping agents, though evidence suggests that this is due
to inhibition of specific redox-sensitive signal transduc-
tion processes related to inflammation, rather than re-
duction in free radicals per se (Floyd et al., 2002). In
studies of agents affecting mitochondrial function, nei-
ther α-lipoic acid (which has antioxidant effects) nor co-
enzyme Q10 (which increases electron transport and
has antioxidant properties) affected life span in mice
(Lee et al., 2004).
As information on pathways and molecular targets
for interventions that may affect longevity accumulates,
the number of promising interventions for mammalian
testing will likely increase. Recently, NIA’s Interventions
Testing Program (discussed below) has initiated four
mouse intervention studies testing effects on longevity
of two anti-inflammatory agents (aspirin and nitroflurbi-
profen), 4-hydroxy-phenyl-N-tert-butyl nitrone (a free
radical scavenger), and nordihydroguarietic acid (a li-
poxygenase inhibitor with structural similarities to the
sirtuin activator resveratrol).
In addition to life span studies, there have been
shorter-term rodent studies on interventions to reverseadverse aging changes by modulating the effects of
putative aging mechanisms. There have been reports
of reduction of age-related declines in cognition by
compounds with antioxidant properties (reviewed in
Golden et al. [2002]). There also have been rodent inter-
vention studies of the effects of agents that modulate
mitochondrial function on aging changes: acetyl-l-car-
nitine administration to old rats increased tissue oxy-
gen consumption and mitochondrial membrane poten-
tial and reversed age-related declines in cognition and
physical activity (Ames, 2004).
Rodent model systems have limitations for evaluat-
ing the likely effect of interventions on humans, be-
cause of the considerable differences in age-related
pathologies between rodents and humans. Nonhuman
primates have greater similarities, but, other than three
ongoing studies of effects of caloric restriction on aging
and life span (Roberts et al., 2001), they have not been
used in intervention studies of aging therapies. The de-
velopment of other animal models of human aging pa-
thologies may be especially valuable for experimental
therapeutic studies.
Short- or medium-term human studies of interven-
tion effects on factors affecting risk for subsequent
aging outcomes. When there is sufficient evidence to
support human testing of interventions, it is necessary
to decide the age of the population to be studied, the
duration of administration of the intervention, and the
outcomes to be measured. If the intervention is ex-
pected to reverse in older persons adverse aging
changes that increase their risk of clinical outcomes, it
may be possible to design a study to measure the ef-
fect of the intervention on these outcomes directly. The
longer the interval needed to observe such an effect,
the more challenging this task becomes. However, clin-
ical trials with treatment periods of up to 8 years have
been successfully organized, and longer trials may be
possible.
If, however, the expected effect of the intervention is
to decelerate aging changes, requiring that it must be
initiated relatively early in life and sustained for de-
cades before clinical effects occur, the logistical chal-
lenges of conducting a trial long enough to detect these
effects are extremely formidable. Except perhaps in
the case of the most promising interventions with abun-
dant preliminary data, alternative designs to determine
shorter-term effects of the intervention can serve as an
intermediate step to screen potential interventions for
longer-term testing. Such studies can be conducted in
different age groups to determine age-related differ-
ences in response and determine, for example, whether
there is a maximum age above which initiating the inter-
vention has no effect.
These studies can examine effects on known risk
factors for clinical outcomes (e.g., bone density and
cholesterol), including effects on rates of age-related
changes in these factors. They can also determine ef-
fects on physiologic functions affected by interventions
that delay or reverse aging changes in laboratory ani-
mals. In addition, there have been attempts to identify
“biomarkers of aging” that could predict very long-term
consequences of aging therapies in humans, including
effects on longevity (Miller, 2001; Butler et al., 2004). In
mice, early life predictors of longevity have been iden-
Cell
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Aeral such human biomarkers have been proposed,
Athese have not been validated by longitudinal epidemi-
vologic data or other evidence regarding their long-term
opredictive value. However, analyses of data from very
dlong-term longitudinal studies may identify such markers.
pIn both human and laboratory animal intervention
sstudies, it is particularly useful to compare the effects
bof the intervention on aging outcomes with its effects
mon its molecular targets in vivo. Such comparisons can
thelp in refining hypotheses about aging mechanisms
as well as in guiding future experimental therapeutic
tstudies. For example, if the in vivo molecular effects of
van intervention are consistent with expectations but its
vclinical or physiologic effects are not, this may cause
rreconsideration of the role that the targeted pathway
Factually plays in the aging outcomes being studied. In
aone specific example, following considerable observa-
rtional evidence that oxidized low-density lipoprotein
i(LDL) played a significant role in progression of athero-
lsclerosis, a human α-tocopherol intervention study
nfound that, although α-tocopherol administration in-
ndeed markedly reduced LDL oxidation, it had no effect
ton atherosclerosis progression (Hodis et al., 2002).
Ascertainment of Adverse as well as Beneficial
oEffects of Interventions
b
A critical issue regarding the identification of therapeu-
h
tic targets in animal models is whether longer life span
v
associated with genetic variants or experimental ma-
s
nipulations is accompanied by maintenance of healthy i
function during this extended lifetime. Possibilities to e
evaluate this in invertebrates are limited by scarcity of m
information on their pathologies. However, the Indymu- d
tation in fruit flies increases longevity “without a con- t
comitant reduction in resting metabolic rate, flight s
velocity, or age-specific fecundity” (Marden et al., 2003). n
The age-1 and daf-2 mutations extend nematode lon- I
gevity and slow tissue degeneration (Garigan et al.,
2002; Herndon et al., 2002) and increase resistance to l
bacterial infection (Garsin et al., 2003; Lithgow, 2003). l
However, not all the effects of all factors that extend b
life span are beneficial. For example, although the long- l
lived Ames dwarf mouse has lower incidence of can- h
cers (Ikeno et al., 2002), it also has developmental ab- a
normalities (Carter et al., 2002) and impairments in t
immune function (Esquifino et al., 1991). T
For interventions in human studies and mammalian i
models, attention to adverse effects as well as to bene- b
ficial effects on aging, is crucial. Few interventions have f
unmitigated benefits; it is unlikely that aging therapies e
will be an exception. Though human studies suggest t
that factors contributing to exceptional longevity also n
contribute to exceptional health over the life span (Hitt
et al., 1999; Atzmon et al., 2004), potential adverse ef- h
fects of any putative human intervention need to be ex- d
plored thoroughly. Studies of effects of interventions in t
laboratory mammals and human cells in vitro not only o
can detect pathologic effects but could dissect the n
mechanisms responsible for them from those that pro- p
duce benefits and could lead to refined interventions d
that slow or reverse adverse aging changes while caus- G
ging minimal risk.nteractions among Intervention Development
ctivities and Resources
s discussed above, the multiple approaches to de-
eloping clinical aging interventions interact with each
ther in several ways. This is illustrated in Figure 1. To
ate, such interactions have mainly been informal, de-
ending on spontaneous collaboration and information
haring among scientists. In the future, there may be
enefits from more structured ways to encourage com-
unication and collaboration on promising lines for in-
ervention development.
One means by which this can be done is by facilita-
ing interactions and collaborative activities among in-
estigators working with diverse approaches and in di-
erse model systems and by providing the resources
elevant to their work in intervention development (see
igure 1): the NIA Longevity Assurance Genes Inter-
ctive Network, involving mainly studies in a wide
ange of laboratory animal models, continues to make
mportant contributions to identifying possible molecu-
ar targets for interventions (Warner, 2003). The large
umber of genes influencing life span identified by this
etwork is likely to continue to expand rapidly as high-
hroughput screening techniques are applied.
To promote rigorous controlled testing in mammals
f interventions that appear particularly promising
ased on available data, the National Institute on Aging
as begun an Interventions Testing Program for inter-
entions that may hold promise for future human
tudies (Warner et al., 2000). In this program, candidate
nterventions are evaluated in terms of the likelihood of
fficacy, and those selected are tested in replicate
ouse studies in three laboratories using standardized
iet and environmental conditions. Information about
he program, including the process for proposing and
electing interventions, is available at http://www.nia.
ih.gov/ResearchInformation/ScientificResources/
nterventionsTestingProgram.htm.
More recently, the Longevity Consortium, involving
arge-scale human population studies working in col-
aboration with researchers in the biology of aging, has
een established to identify polymorphisms affecting
ongevity, including variants in homologs of genes that
ave effects on longevity in laboratory animals (Hadley
nd Rossi, 2005). Additional information on the consor-
ium is available at http://www.longevityconsortium.org/.
his research should be useful in identifying or confirm-
ng targets or pathways for intervention. NIA has also
egun a program to develop and screen compounds
or new drug targets for age-related conditions, pres-
ntly focused on neurodegenerative diseases, diabe-
es, congestive heart failure, and oncologic and immu-
ologic diseases.
Identification of long-term predictors of exceptionally
ealthy aging, which could be used in short- and me-
ium-term human intervention studies, could be facili-
ated by the recently organized NIA Longitudinal Data
n Aging Working Group, comprising researchers from
umerous epidemiologic studies, which is examining
ossibilities for enhanced uses and analyses of longitu-
inal data in aging research. The report of the Working
roup’s first meeting is available at http://www.nia.nih.
ov/ResearchInformation/ConferencesAndMeetings/.
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561Figure 1. Aging Therapies: Developmental Activities, Interactions, and Resources
See text for discussion.Specific Therapies
This section discusses selected examples that il-
lustrate the considerations discussed in preceding sec-
tions and also illustrate how development of new thera-
pies is stimulated by different types of preliminary
evidence, i.e., by biologic findings implying a cellular
structure’s role in aging (telomeres), by laboratory ani-
mal intervention studies (caloric restriction), and by in-
vestigations of the consequences of “normal” aging
changes (vascular stiffening).
Telomere Maintenance
Critical observations by Hayflick and collaborators in
the 1960s demonstrated that replicative capacity of
normal somatic cells is finite and that, after a critical
number of cell divisions, cells reach a state in which
further division cannot occur, a state termed replicative
senescence (Hayflick, 1965). This observation in turn
raised the question of what biological process provides
the counting mechanism that monitors cell division and
underlies replicative senescence. Research over the
past 15 years has provided an intriguing answer to this
question in identifying the role of telomere function in
regulating cell replication and senescence (reviewed by
McEachern et al. [2000]). DNA replication during mito-
sis is incomplete and results in loss of 50–200 terminal
bp per cell division. This loss of DNA occurs in telo-
meres, the tandem hexanucleotide repeats that consti-
tute the ends of linear chromosomes. When cumulative
loss of telomeres results in critical shortening, the “cap-
ping” function of telomeres is compromised, and re-
cognition of this altered telomere structure results in
cell senescence and/or apoptotic death. A pivotal dis-
covery was the identification of telomerase, an RNA-
dependent DNA polymerase that is capable of synthe-
sizing terminal telomere repeats and extending the
length of telomeres, thus compensating for the telo-
mere loss that occurs with cell division. The potentialimplications of these findings for human aging and for
clinical intervention have provoked substantial interest.
The role of telomeres in regulating the capacity for
cell division, and the ability to extend cell division by
intervening to manipulate telomere length and function
have been well established. Cultured human cells reach
replicative senescence after cell division in culture and
generally express little or no detectable telomerase
activity by the time that they are approaching senes-
cence. Induction of telomerase activity in normal hu-
man somatic cells has been accomplished by trans-
duction of telomerase genes and has been shown to
result in the “immortalization” of these cells, as defined
by an apparently unlimited capacity for cell division
(Bodnar et al., 1998). An important question now under
study is whether these immortalized cells retain their
normal function or are altered in clinically relevant re-
spects, such as loss of normal function or increased
risk of malignant transformation.
What is the evidence that altered telomere length or
function has consequences for multicellular organisms
in vivo? Direct and compelling evidence comes from
seminal experiments in which telomerase activity is
eliminated by inactivation of telomerase genes. These
experiments have been carried out in a number of spe-
cies, but of most apparent clinical relevance are the
studies carried out in knockout mice as a mammalian
model (Blasco et al., 1997). During successive genera-
tions of breeding, telomeres progressively shorten, re-
sulting in sterility due to the failure of both female and
male germ cell lineages. Mice that have reached these
late generations of telomere shortening also show a
number of abnormalities similar to some if not all as-
pects of premature aging (Rudolph et al., 1999).
What, then, is the evidence that altered telomere
function plays a role in normal human aging or in clin-
ical conditions? There is considerable indication that
Cell
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fduring normal human aging and that accelerated telo-
Hmere shortening can occur in specific cell types and
under disease-associated circumstances. These lines
iof evidence are consistent with but do not prove the
iexistence of a causal relationship between telomere
oshortening and disease- or age-related changes in hu-
amans. In this regard, two recent findings are of particu-
tlar note. In a study of men and women aged 60–97, it
twas observed that telomere length in peripheral blood
scells is related to subsequent survival, with long telo-
rmeres associated with significantly lower risk of death
p(Cawthon et al., 2003). This correlation is intriguing, al-
pthough it is not a direct demonstration that telomere
length is a direct determinant of survival. The alterna-
etive possibility consistent with these findings is that
tgenetic or life course events affect survival and that
vtelomere length is affected in parallel but is an epiphe-
Inomenon rather than a causal determinant of health or
dsurvival. Perhaps the most compelling evidence for the
nexistence of such a causal relationship is the inherited
pdisease dyskeratosis congenita (DKC), the autosomal
idominant variant of which is caused by a mutation in
bthe telomerase RNA template gene and the X-linked
tvariant of which is caused by mutations in the telo-
mere-associated protein dyskerin (Mitchell et al., 1999;
eVulliamy et al., 2001). DKC is marked by abnormally
rshort telomeres, defects in epithelial and hematopoietic
ncell lineages, and hematopoietic malignancies. These
cfindings suggest that telomere length or telomerase ac-
ttivity can affect human health.
sWhat are the strategies by which existing information
acould be translated into therapeutic manipulations of
ptelomeres? The most accessible approaches at present
bappear to be those in which specific human cells would
mbe manipulated ex vivo, for example, by telomerase
mgene transduction to express telomerase, maintain or
eincrease telomere length, and therefore to have ex-
stended capacity for cell division. Cells so modified
ucould then be administered to the same individual un-
hder circumstances in which cell numbers or potential
for cell division would otherwise be insufficient to serve
tthe desired outcomes. Such approaches will require
F
close attention to potential complications such as un-
i
controlled division or altered function of modified cells.
s
t
Caloric Restriction h
Chronic caloric restriction (CR) (“undernutrition without I
malnutrition”), when started in early life or adult life, 2
substantially extends life span in rodents as well as in y
multiple invertebrate species. The fact that this single a
intervention slows multiple age-related changes, de- d
lays the onset of cancer and multiple other age-related M
pathologies, and extends life span is consistent with m
(but does not prove) the idea that one or a few mecha- c
nisms, modulated by caloric restriction, control the rate w
of multiple aging changes and may be potentially con- t
trollable by other interventions as well. Chronic CR in t
nonhuman primates has been found to produce parallel i
physiologic changes to those seen in rodents; studies a
of its effects on nonhuman primate life span have not a
been completed. Despite extensive research on caloric a
restriction’s effects on aging, we still do not understandhe mechanism(s) of its effects nor their implications
or humans (Hadley et al., 2001; Roberts et al., 2001;
ursting et al., 2003; Koubova and Guarente, 2003).
There is also evidence that periodic food deprivation
n mice, produced by every-other-day intermittent feed-
ng, may induce similar physiologic effects over a period
f weeks to those of caloric restriction, even when
verage daily intake is minimally different from ad libi-
um intake (Anson et al., 2003). This finding has poten-
ially very important implications. However, a life span
tudy in which caloric intake on an intermittent feeding
egimen is documented to equal ad libitum intake and
roduce equivalent effects to CR’s has yet to be re-
orted.
Molecular and physiologic mechanisms proposed to
xplain CR’s effects on life span are essentially coex-
ensive with those proposed to regulate life span (re-
iewed in Masoro [2000], Koubova and Guarente [2003],
ngram et al. [2004]), including reduction of oxidative
amage, increased metabolic efficiency, increased ge-
omic stability, decreased apoptosis, increased apo-
tosis, lowered glucose levels, slowed glycolysis, lower
nsulin levels, lowered protein glycation, decreased
ody temperature, neuroendocrine responses, and sir-
uin activation.
Exploration of potential human implications of the
xtension of life span by CR has taken two general di-
ections. One derives from the search for the mecha-
isms mediating its effects in laboratory animals, which
ould be used to identify “CR mimetic” interventions
hat produce CR’s effects in the absence of caloric re-
triction (Hadley et al., 2001). Since almost every mech-
nism proposed to modulate aging changes has been
roposed to modulate CR’s effects on aging, in the
roadest sense, almost all studies of interventions that
odulate these mechanisms could be considered CR
imetic studies. In addition to such studies discussed
arlier, there have been recent CR mimetic intervention
tudies in rodents focused on glucose metabolism,
sing the glycolysis inhibitor 2-deoxyglucose and the
ypoglycemic agent metformin (Ingram et al., 2004).
Another potential line of research on human implica-
ions of CR’s effects on aging is controlled human trials.
or reasons discussed above, medium-term studies of
ts effects are advisable before considering longer-term
tudies. NIA is supporting randomized controlled pilot
rials of CR, collectively known as CALERIE (Compre-
ensive Assessment of Long-term Effects of Restricted
ntake of Energy Intake). CALERIE will test effects of
–3 years of caloric restriction (20%–30% reduction) in
oung and middle-aged nonobese persons. CR will
lso be compared with exercise interventions that pro-
uce weight loss to determine how their effects differ.
ajor goals of CALERIE are to determine whether this
agnitude and duration of CR is feasible and safe, to
ompare human physiologic and cellular responses
ith effects reported in laboratory animals, and to de-
ermine its effects on disease risk factors and predic-
ors of longevity derived from human studies. CALERIE
s encouraging proposals for ancillary studies on mech-
nisms underlying CR’s physiologic effects. Information
bout CALERIE, including ancillary study policies, is
vailable at http://calerie.dcri.duke.edu/.
If findings from CALERIE indicate feasibility and
Review
563safety, a trial of a longer CR intervention may be worth-
while, particularly if CALERIE interventions have favor-
able effects on known disease risk factors. Prospects
for long-term CR studies may be enhanced by the
rapidly increasing understanding of the regulation of
food intake and the possible ensuing development of
better anorexiants (Flier, 2004).
Interventions against Age-Related
Vascular Stiffening
One of the most salient age-associated changes in
large arteries is an increase in intimal-medial thickness,
which is accompanied by an increase in stiffness. A
growing body of epidemiologic evidence indicates that
these changes, and the ensuing increase in systolic
and pulse pressure, formerly thought to be part of “nor-
mal” aging, precede and predict a higher risk for de-
veloping clinical atherosclerosis, hypertension, and myo-
cardial infarction or stroke (Lakatta and Levy, 2003). In
other words, aging blood vessels provide a milieu in
which vascular diseases can flourish. These vascular
changes that accompany aging in persons who do not
have a diagnosis of clinical cardiovascular disease,
however, largely have remained outside the bailiwick of
clinical medicine and have not been the focus of pre-
ventive measures. However, if such “risky” arterial aging
leads to arterial disease, it offers potential targets for
treatment and prevention, involving modification of life-
style or pharmacotherapy, to retard its rate of pro-
gression and delay or prevent clinical disease.
Cellular and molecular mechanisms that underlie ar-
terial intimal medial thickening and stiffening with ad-
vancing age may provide targets for such interventions.
These include elevated levels or activity of molecules
such as matrix metalloprotease-2 (MMP2), angioten-
sin II (AngII), transforming growth factor β, monocyte
chemoattractant protein-1 (MCP1), interstitial cell ad-
hesion molecule-1, and NADPH oxidase. Each of these
factors is a signaling target downstream of the angio-
tensin AT1 receptor. AngII increases MMP2 activity in
the aged arterial wall and increases transcription of
TGFβ and the TGFβ II receptor. Activated MMP2 acti-
vates TGFβ, leading to enhanced transcription of fibro-
nectin and collagen genes. AngII signaling also in-
creases the production of MCP1 and its receptor,
CCR2, in arterial endothelial and vascular smooth mus-
cle cells. Another sign of increased inflammation is en-
hanced NADPH oxidase activity, which also results in
part from an age-associated increase in arterial AngII
signaling. Excessive NADPH oxidase produces super-
oxide, which reacts with nitric oxide to produce the
toxic species peroxynitrite, which can lead to protein
nitration and “steals” nitric oxide in the process, reduc-
ing its bioavailability.
Interactions among these factors create a metaboli-
cally active environment (Lakatta, 2003; Spinetti et al.,
2004; Wang et al., 2003). Some vascular smooth muscle
cells (VSMCs) shift their phenotype from contractile to
secretory, proliferative, and invasive and migrate into
the thickened intima. Enhanced VSMC invasion within
the older arterial wall is promoted by elaboration of the
chemoattractant PDGFβ and its receptor, both of which
are also downstream signaling effects of Ang II. VSMC
invasion of matrix within the old arterial wall is facili-
tated both by activated MMP2 and by MCP1. Arterialwall elastin becomes fragmented with advancing age,
and excessive collagen is synthesized and becomes
nonenzymatically glycated. Endothelial dysfunction
and its attendant alterations in endothelial permeability
and vasotonic actions occur. These same metabolic,
enzymatic, cellular, and endothelial alterations appear
to play a critical role in the genesis or promotion of
hypertension, atherosclerosis, vascular inflammation,
vascular remodeling, and oxidant stress. In other
words, many of the same factors that underlie the age-
associated structural and functional alterations of the
arterial intima and media are also implicated in the
pathogenesis of clinical arterial disease. These and
other factors are the “culprits” that underlie the “risky”
component of arterial aging in humans (Lakatta, 2003).
As progress is made in further elucidating the diverse
molecular mechanisms that underlie the arterial alter-
ations that accompany advancing age, novel therapies
must emerge that will specifically target these path-
ways and retard or reverse “unsuccessful” arterial
aging. Treatments targeting structural factors have be-
gun. Nonenzymatic crosslinks between glucose (or
other reducing sugars) and amino groups that generate
advanced glycation end products alter long-lived pro-
teins, e.g., collagen and elastin, and increase with ad-
vancing age, and both cause arteries and the heart to
stiffen. NIA studies have demonstrated that ALT-711,
a novel thiazolium agent that breaks such crosslinks,
reduces arterial stiffness both in nonhuman primates
(Vaitkevicius et al., 2001) and in humans (Kass et al.,
2001). Chronic inhibition of angiotensin receptor signal-
ing also substantially retards the age-associated
increase in collagen content and intimal-medial thick-
ening and stiffness in rodents (see Lakatta [2003] for
review).
The substantial variability among older persons in the
degree of these vascular changes also reinforces the
possibility of identifying factors that modify them (La-
katta and Levy, 2003), including lifestyle factors: it is
noteworthy that arterial stiffness is inversely related to
physical fitness, assessed as maximum oxygen con-
sumption, over a broad age range (Vaitkevicius et al.,
1993). To date, however, clinical trial findings on the ef-
fects of physical activity on vascular stiffness have not
been reported. Dietary interventions can modulate vas-
cular properties. Food fat content has been shown to
adversely affect vascular stiffness and endothelial func-
tion; diets that are reduced in sodium are associated
with reduced arterial stiffening with aging, independent
of their blood pressure-lowering effects (Gates et al.,
2004).
While such preventive lifestyle or pharmacological
strategies may be explored even now, future genetic
characterization of individuals will likely allow person-
specific stratification with respect to risk, efficacy, and
cost effectiveness of measures to retard vascular aging
in order to reduce CV functional disability and disease
at older ages.
Alzheimer’s Disease
Alzheimer’s disease (AD) is a devastating neurodegen-
erative disease that afflicts older men and women, with
risk increasing dramatically with age. Alzheimer’s dis-
ease research has stimulated not only knowledge of the
disease but also understanding of normal brain aging
Cell
564and the ways in which aging of the brain both contrib- A
outes to and differs from the pathology of AD. Knowl-
edge gained from multiple avenues of research il- h
(lustrates the way in which genetic, molecular, and
epidemiologic information can be translated into pre- t
iclinical and clinical interventions.
In the early 1900s, Alois Alzheimer described the am- r
myloid plaques and neurofibrillary tangles characteristic
of AD. Sequencing of the protein component of brain b
2amyloid in the 1980s was followed soon thereafter by
identification of the gene encoding its precursor pro- v
ttein, amyloid precursor protein (APP). Subsequently, it
was found that mutations in the APP gene are responsi-
cble for some cases of familial early onset AD; that other
cases of familial early onset AD are caused by muta- c
ations in two other genes, presenilins 1 and 2; and that
mutations in all three of these genes increased the pro- a
tduction of specific forms of amyloid. These molecular
and genetic discoveries focused research on the path- r
tways leading to amyloid formation and accumulation of
plaques. The enzymes β- and γ-secretase cooperate to b
ncleave APP and produce the peptide form, β-amyloid,
that preferentially constitutes plaques in the brains of N
wAD patients, making inhibition of these enzymes a
target of current drug development strategies (history s
sreviewed in Hardy and Selkoe [2002]). The enzyme
α-secretase cleaves β-amyloid internally, potentially w
preventing the formation of plaques; enhancing the ac-
tivity of α-secretase thus represents another target s
c(Lichtenthaler and Haass, 2004). Yet another is degra-
dation of amyloid (Tanzi et al., 2004) or preventing the e
taccumulation of soluble, possibly highly toxic interme-
diates (Klein et al., 2001). The challenge of designing t
teffective interventions that inhibit AD-specific path-
ways but do not interfere with essential normal func- 1
Ations is illustrated by the example of γ-secretase,
which, apart from its role in β-amyloid production, is d
falso the protease responsible for cleavage and activa-
tion of notch, a receptor that is involved in a diverse O
dset of normal differentiative pathways (Conboy et al.,
2003). This raises the possibility, being actively investi- c
vgated by a number of researchers, that altered preseni-
lin function may also lead to neurodegenerative disease a
tby other, nonamyloidogenic pathways (Thinakaran and
Parent, 2004). p
2The identification of mutated APP and presenilin
genes that are causal for AD has also led to the devel- v
opment of the first transgenic mouse models of this
disease, providing model systems for testing of amy- h
cloid interventions in vivo. Experimental treatments
tested in these models to date include the successful s
lreduction in amyloid plaque formation by chelation
(Cherny et al., 2001) and by immunization against amy- c
mloid (Schenk et al., 1999). Clinical trials of immunization
with amyloid peptide were initiated in humans but were m
pstopped due to side effects of encephalopathy (Orgo-
gozo et al., 2003). Researchers continue to explore dif- g
tferent approaches to immunotherapy that would re-
duce amyloid load without negative side effects. t
ONeurofibrillary tangles are another obvious target for
intervention. Research on metabolism of their protein c
tcomponent, tau, has led to insights into phosphoryla-
tion and other modifications of tau that favor tangle for- i
tmation and dissolution of the microtubule network.gain, genetics has played a role in highlighting the role
f tau, since a number of mutations in the tau gene
ave been shown to cause frontotemporal dementia
FTDP-17) and related dementias (Ingram and Spillan-
ini, 2002). The link between tau and amyloid pathology
n AD is not yet clear, nor is the link between age-
elated accumulation of tau or amyloid and develop-
ent of AD. Research on multiply transgenic mice com-
ining abnormalities in amyloid and tau (Oddo et al.,
004) is beginning to elucidate the relationships. Inter-
entions targeting tau phosphorylation and stabiliza-
ion of microtubules are being developed.
Understanding of genetic factors in the much more
ommon late onset form of AD was initiated by the dis-
overy that the E4 allele of the apolipoprotein gene is
major risk factor gene for the disease (Strittmatter et
l., 1993), leading to research on the mechanisms of
his effect and possible therapeutic targets. No other
isk factor genes have yet been unambiguously iden-
ified, although several regions of the genome have
een pinpointed. The NIA’s genetics initiative http://www.
ia.nih.gov/ResearchInformation/ExtramuralPrograms/
euroscienceOfAging/AlzheimersDiseaseGenetics.htm;
ww.ncrad.org) will make available to qualified re-
earchers well-characterized family and case control
ets presently being identified by the AD Centers (http://
ww.alzheimers.org/adcdir.htm) and other investigators.
Even early stages of AD are characterized by loss of
ynapses and neurons in entorhinal cortex and hippo-
ampus, areas important for memory. The anteced-
nt(s) of cell death are unknown. Possible interventions
argeting cell dysfunction and death include introduc-
ion of growth factors into affected brain regions, a
echnique effective in nonhuman primates (Smith et al.,
999) and presently the focus of a small clinical trial in
D patients. Stimulating endogenous stem cell pro-
uction of neurons may positively affect hippocampal
unction (Kuhn et al., 1996; Kempermann et al., 2004).
ther possible targets, common to a number of neuro-
egenerative diseases, include boosting the pathways
learing abnormally folded and toxic proteins and de-
eloping strategies to reduce abnormal folding (Ross
nd Poirier, 2004). Techniques for assessing levels of
housands of individual mRNAs will reveal underlying
atterns of mRNA and protein changes (Blalock et al.,
004), identifying altered pathways early in disease de-
elopment.
Both AD brain pathology and epidemiological studies
ave implicated oxidative stress and inflammation as
ausal factors in AD. Diets enriched in antioxidants,
uch as vitamins C and E and α-lipoic acid improve
earning and memory and reduce plaque load in aged
anines (Milgram et al., 2004) and rats, and anti-inflam-
atory agents reduce plaque load in APP transgenic
ice (Lim et al., 2001; Eriksen et al., 2003). Long-term
revention clinical trials for several antioxidants are on-
oing. Participants in a recently suspended prevention
rial of nonsteroidal anti-inflammatory drugs will con-
inue to be followed for safety and efficacy for 2 years.
ther risk factors for AD include several also related to
ardiovascular disease—high blood pressure, choles-
erol, and homocysteine levels. A statin is being tested
n a clinical trial on patients who have AD, and another
reatment trial tests efficacy of reduction in blood homo-
Review
565cysteine levels by folate/B6/B12. The effect on AD risk
of lowering blood glucose levels is being tested in older
diabetics. Data on most of these trials can be accessed
at http://www.alzheimers.org/clintrials/search.asp.
Research on AD initially focused on late stage dis-
ease, but with better understanding and more sophisti-
cated research tools, the focus has shifted to earlier
and even preclinical stages (Grundman et al., 2004). It is
likely that AD pathology is initiated many years before
clinical diagnosis; by the time a person has mild cog-
nitive impairment (MCI) with memory decline, loss of
key neurons in the entorhinal cortex is profound (Price
et al., 2001), and loss of neuronal function is apparent
in other brain regions as well (Mufson et al., 2002). Im-
portant initiatives will therefore focus on developing
prevention strategies that would slow or halt the pa-
thology before major functional impairment. Key to
early identification of persons at risk is the develop-
ment of neuropsychological, clinical, and imaging tech-
niques sensitive to characteristic early pathologies
such as delayed recall memory measures, loss of hip-
pocampal volume, and lowered metabolism in affected
brain regions. Identification of suitable imaging and bi-
ological makers of progression would be critical to re-
ducing the size, time, and cost of treatment and pre-
vention trials. The AD Neuroimaging Initiative (ADNI)
(http://www.alzheimers.org/pubs/conv11n1and2.
htm#new) is a major new longitudinal study of normal
controls and persons with MCI and AD to identify surro-
gate markers for disease onset and progression and is
potentially a scaffold for ancillary studies testing spe-
cific hypotheses.
Conclusion
In recent years, cellular, molecular, and genetic studies
of aging in in vitro models and in short-lived inverte-
brates have generated an impressive pace of discovery.
These discoveries, together with outcomes of epidemi-
ologic and clinical research, have in turn helped to iden-
tify potential therapeutic targets for testing in longer-lived
mammalian species. It is important that this pace of
progress continue, with application of cutting-edge ba-
sic science. It will also be critical to develop strategies
that will allow selection of the most promising of candi-
date interventions suggested by in vitro and inverte-
brate studies, and by laboratory mammal and human
studies, for further evaluation.
As illustrated in this review, in all aspects of the de-
velopment of interventions that target aging-related
processes, from in vitro to clinical studies, there are
needs and opportunities for innovative molecular and
cellular research strategies. Aging is a fundamental bio-
logical phenomenon with wide-ranging medical and so-
cietal effects. The discovery of effective new therapies
to address it is a worthy challenge for molecular and
cell biology.
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